Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 2:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 415 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ARDS (Acute Respiratory Distress Syndrome) Clear all
Terminated No phase listed Observational

Low-Level Laser Therapy Treatment of Lung Inflammation in Post-COVID-19 Recovery

NCT05258617
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome
Interventions
LLLT Photobiomodulation
Device
Lead sponsor
Ward Photonics LLC
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Berkeley, California • Los Angeles, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 14, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)

NCT00351533
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Fish oil (eicosapentaenoic acid and docosahexanoic acid)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Boise, Idaho • Portland, Oregon • Burlington, Vermont + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Oct 14, 2026, 2:21 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Alveolar Macrophage Programming Following Endotoxin Exposure

NCT03859050
View directory record Official record
Conditions
ARDS, Human
Interventions
bronchoscopy with intrabronchial administration of lipopolysaccharide
Other
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2032
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 14, 2026, 2:21 PM EDT
Suspended Phase 2 Interventional

Pediatric Acute Respiratory Distress Syndrome (ARDS) Management Trial

NCT07123961
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), Ventilator Management, Lung-protective Ventilation, Pediatric Acute Respiratory Distress Syndrome (PARDS)
Interventions
High Driving Pressure Mechanical Ventilation, Low Driving Pressure Mechanical Ventilation
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Weeks to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 14, 2026, 2:21 PM EDT
Completed Phase 3 Interventional

Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)

NCT00000579
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Lung Diseases
Interventions
Low Tidal Volume Ventilation, Positive End-Expiratory Pressure, Lysofylline, Methylprednisolone, Ketoconazole, Fluid Management, Pulmonary Artery Catheter
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2004
U.S. locations
20
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 14, 2026, 2:21 PM EDT
Completed Not applicable Interventional

Early Caffeine and LISA Compared to Caffeine and CPAP in Preterm Infants

NCT04209946
View directory record Official record
Conditions
Premature Lungs, Respiratory Distress Syndrome, Surfactant Deficiency Syndrome Neonatal
Interventions
Less Invasive Surfactant Administration LISA, Continuous Positive Airway Pressure CPAP
Procedure
Lead sponsor
Sharp HealthCare
Other
Eligibility
24 Weeks to 29 Weeks
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Irvine, California • Loma Linda, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 14, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates

NCT02074059
View directory record Official record
Conditions
Respiratory Distress Syndrome
Interventions
Lucinactant for Inhalation, nCPAP alone
Drug · Device
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
29 Weeks to 34 Weeks
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 14, 2026, 2:21 PM EDT
Terminated Not applicable Interventional

Open Lung Strategy, Gas Distribution and Right Heart Function in ARDS Patients

NCT03202641
View directory record Official record
Conditions
ARDS, Human, Lung Injury, Acute, Respiratory Distress Syndrome, Mechanical Ventilation Complication, Alveolar Edema, Right Heart Failure, Right Ventricular Dysfunction
Interventions
PEEP ARDSnet, PEEP LRM
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 14, 2026, 2:21 PM EDT
Recruiting No phase listed Observational

The APS Phenotyping Study

NCT06521502
View directory record Official record
Conditions
ARDS, Sepsis, Pneumonia
Interventions
Blood collection, Urine Collection, Nasal, oral, and rectal swabs, Stool collection, Heat Moisture Exchange Filter collection, Tracheal Aspirate sample collection, Non-bronchoscopic bronchoalveolar lavage (NBBAL), Surveys, Short physical performance battery, Hand grip strength, CNS Vital Signs, Muscle Ultrasound, Muscle Strength, Spirometry, Lung Diffusion Testing (DLCO), Chest CT Scan
Other · Procedure · Radiation
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
20
States / cities
Fresno, California • Palo Alto, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 14, 2026, 2:21 PM EDT
No Longer Available No phase listed Expanded access

SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

NCT04355494
View directory record Official record
Conditions
COVID-19, Pneumonia, Viral, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Interventions
eculizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
7
States / cities
Los Angeles, California • Boston, Massachusetts • Newton, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 14, 2026, 2:21 PM EDT
Completed Not applicable Interventional

LISA in the Delivery Room for Extremely Preterm Infants

NCT04715373
View directory record Official record
Conditions
Extreme Prematurity, Respiratory Distress Syndrome
Interventions
LISA
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
5 Minutes to 20 Minutes
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 14, 2026, 2:21 PM EDT
Recruiting Phase 3 Interventional

InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS

NCT05960929
View directory record Official record
Conditions
Respiratory Distress Syndrome (Neonatal), Intubation Complication, Death; Neonatal
Interventions
Infasurf Aero™
Combination Product
Lead sponsor
ONY
Industry
Eligibility
29 Weeks to 36 Weeks
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 14, 2026, 2:21 PM EDT
Completed Phase 1 Interventional Results available

Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)

NCT04530604
View directory record Official record
Conditions
COVID, Sars-CoV2, COVID-19, Acute Respiratory Distress Syndrome
Interventions
Defibrotide
Drug
Lead sponsor
Gregory Yanik
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 14, 2026, 2:21 PM EDT
Completed Not applicable Interventional Results available

Extending CPAP Therapy in Stable Preterm Infants to Increase Lung Growth and Function

NCT04295564
View directory record Official record
Conditions
Neonatal, Premature Birth, Respiratory Distress Syndrome
Interventions
Additional 2 weeks of CPAP
Other
Lead sponsor
Cynthia McEvoy
Other
Eligibility
1 Day to 12 Weeks
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 14, 2026, 2:21 PM EDT
Active, not recruiting No phase listed Observational

Post Acute Sequelae of COVID-19

NCT04964115
View directory record Official record
Conditions
Covid19, Sars-CoV-2 Infection, Dyspnea Caused by 2019-nCoV, COVID-19 Acute Respiratory Distress Syndrome, Pulmonary Fibrosis
Interventions
Cohort study
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 14, 2026, 2:21 PM EDT
Terminated Phase 2 Interventional Results available

Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA

NCT02528318
View directory record Official record
Conditions
Respiratory Distress Syndrome
Interventions
Lucinactant for inhalation, nCPAP alone
Combination Product · Device
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
26 Weeks to 28 Weeks
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Loma Linda, California • San Diego, California • Newark, Delaware + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 14, 2026, 2:21 PM EDT
Active, not recruiting No phase listed Observational

ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)

NCT05388708
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Interventions
ECMO support, PROSpect protocolized therapies
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
14 Days to 20 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 14, 2026, 2:21 PM EDT
Terminated Phase 2 Interventional Results available

Study of Varespladib in Patients Hospitalized With Severe COVID-19

NCT04969991
View directory record Official record
Conditions
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Varespladib, Placebo
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Ventura, California • Miami, Florida • Munster, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 14, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

Losartan for Patients With COVID-19 Requiring Hospitalization

NCT04312009
View directory record Official record
Conditions
Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
Interventions
Losartan, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 14, 2026, 2:21 PM EDT
Completed No phase listed Observational

Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns

NCT00006058
View directory record Official record
Conditions
Respiratory Distress Syndrome, Bronchopulmonary Dysplasia
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111

NCT04388826
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Veru-111
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Scottsdale, Arizona • Saint Louis Park, Minnesota • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 14, 2026, 2:21 PM EDT
Terminated Phase 2 Interventional Results available

Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)

NCT04502433
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
CUROSURF® (poractant alfa)
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 14, 2026, 2:21 PM EDT
Recruiting Phase 4 Interventional

Non Inferiority Trial Investigating Surfactants Administered Via MIST

NCT06074380
View directory record Official record
Conditions
Respiratory Distress Syndrome
Interventions
MIST surfactant
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
Up to 48 Hours
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 14, 2026, 2:21 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity?

NCT02939742
View directory record Official record
Conditions
PPROM, Respiratory Distress Syndrome in Premature Infants
Interventions
Betamethasone, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 14, 2026, 2:21 PM EDT